NBIXNeurocrine Biosciences, Inc.
$142.40-1.9% 1Y
$142.40
$123.1052 weeks$182.85
The financials
Neurocrine Biosciences, Inc. by the numbers
Neurocrine Biosciences, Inc. (NBIX) reported revenue of $959M in Q2 2026 (quarter ended Jun 30, 2026), up 39% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $144M (15% of revenue). For the full year FY2025, revenue was $2.86B (+21% year on year) and net income $479M. Its largest product in Q1 2025 (quarter ended Mar 31, 2025) was Collaboration at $8.9M, 57% of the disclosed total, ahead of Royalty at 43%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $959M | $688M | +39% |
| Gross profit | $936M | $676M | +38% |
| Operating income | $152M | $146M | +4.1% |
| Net income | $144M | $108M | +34% |
| Diluted EPS | $1.39 | $1.06 | +31% |
| Product | Revenue | Share |
|---|---|---|
| Collaboration | $8.9M | 57% |
| Royalty | $6.7M | 43% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $4.7M (+34%)
Collaboration grew -15% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$4.7M$4.7Mquarter on quarter +34%year on year -15%+34%-15%
On our screens:Cheap stocks by free cash flow yield
Drug Manufacturers, Specialty & Generic
Ranks #6 of 41 by RyuScore